Pharmaceuticals, Biotechnology and Life Sciences
Second quarter revenue $2,521 million and Adjusted EBITDA $483 million GAAP Diluted Earnings per Share $(0.12); Adjusted Diluted Earnings per…
Second quarter revenue $2,521 million and Adjusted EBITDA $483 million GAAP Diluted Earnings per Share $(0.12); Adjusted Diluted Earnings per…
DUBLIN–(BUSINESS WIRE)–The “Sterols – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. The publisher brings years…
DUBLIN–(BUSINESS WIRE)–The “Sterols – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. The publisher brings years…
-Trial is evaluating the safety and efficacy of farnesoid X receptor (FXR) agonist TERN-101 in NASH patients – FOSTER CITY,…
Proceeds will support clinical development of lead program, T3P-Y058-739, poised to enter clinical trials in 2021 BASEL, Switzerland–(BUSINESS WIRE)–T3 Pharmaceuticals…
COPENHAGEN–(BUSINESS WIRE)–MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard of topical therapies for chronic inflammatory conditions, announced…
Multi-year, multi-study collaboration includes two adaptive phase 2 trials with DS-1062 in lung cancer and patritumab deruxtecan (U3-1402) in breast…
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology…
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology…